AIM
AIM ImmunoTech Inc.1.3800
+0.0600+4.55%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
4.06MP/E (TTM)
-Basic EPS (TTM)
-18.18Dividend Yield
0%Recent Filings
8-K
10-Q
8-K
Amends certificate of incorporation
AIM ImmunoTech amended and restated its Certificate of Incorporation on October 29, 2025, filing the updated document with the SEC to consolidate prior versions. This housekeeping move streamlines governance without altering core operations or shareholder rights. No financial impacts disclosed. Filing reflects routine compliance.
8-K
AIM at Maxim Summit
AIM ImmunoTech disclosed its participation in the Maxim Growth Summit 2025 on October 22-23 in New York, furnishing a presentation on Ampligen's potential for treating viral diseases, cancers, and immune disorders. The event highlights ongoing clinical efforts, yet forward-looking claims carry risks like trial failures and regulatory hurdles. No financial impacts disclosed.
10-Q
Q2 FY2025 results
AIM ImmunoTech's Q2 FY2025 results show revenue dipping to $25K from $50K y/y, driven by fluctuating patient participation in its Ampligen cost recovery program, while operating loss narrowed to $(2.6)M from $(3.7)M y/y as R&D edged up 2.5% to $1.2M on clinical trials but G&A fell 43% to $1.5M from cost controls. Net loss widened to $(2.8)M or $(3.68) per share from $(1.8)M or $(3.00), with the gap over operating loss tied to interest expense and minor investment losses; EPS aligns with 759K diluted shares, no anti-dilution flagged. Cash burned $3.9M YTD on operations versus $7.8M last year, ending at $476K plus $359K marketable investments, while $2.3M current debt matures soon under a Streeterville note at 10% with full availability. No M&A or non-GAAP metrics disclosed in the 10-Q. Yet regulatory hurdles loom large.
ADPT
Adaptive Biotechnologies Corpor
15.93+0.24
ALGS
Aligos Therapeutics, Inc.
11.47-0.53
ALT
Altimmune, Inc.
5.03-0.25
AVTX
Avalo Therapeutics, Inc.
18.82+1.12
AXIM
Axim Biotechnologies, Inc.
0.02+0.00
CYTOF
Altamira Therapeutics Ltd.
0.07+0.00
IMA
ImageneBio, Inc.
6.25+0.08
IMMX
Immix Biopharma, Inc.
5.94-0.27
IMNN
Imunon, Inc.
3.88-0.09
REPL
Replimune Group, Inc.
9.61-0.34